Revance Therapeutics Future Growth
Future criteria checks 2/6
Revance Therapeutics is forecast to grow earnings and revenue by 68.8% and 22.6% per annum respectively. EPS is expected to grow by 71.4% per annum. Return on equity is forecast to be -42.7% in 3 years.
Key information
68.8%
Earnings growth rate
71.4%
EPS growth rate
Pharmaceuticals earnings growth | 27.6% |
Revenue growth rate | 22.6% |
Future return on equity | -42.7% |
Analyst coverage | Good |
Last updated | 05 Jun 2024 |
Recent future growth updates
Recent updates
What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You
Mar 04Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain
Feb 29Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%
Dec 28Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be
Nov 10Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt
Aug 10Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors
Jun 14Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?
Apr 17Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt
Jan 02Revance Therapeutics submits sBLA for Daxxify for cervical dystonia
Oct 20Revance climbs 14% as FDA approves facial injectable for frown lines
Sep 08Revance Therapeutics: More Risk To Sept. 8 PDUFA Than It Seems
Aug 24Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?
Aug 04Revance: Potential Comeback On FDA Resubmission For DAXI
Jul 15Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt
Apr 17Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 475 | -19 | 42 | 100 | 10 |
12/31/2025 | 372 | -90 | -45 | 0 | 11 |
12/31/2024 | 278 | -190 | -125 | -43 | 11 |
3/31/2024 | 240 | -325 | -221 | -213 | N/A |
12/31/2023 | 234 | -324 | -223 | -217 | N/A |
9/30/2023 | 211 | -403 | -210 | -204 | N/A |
6/30/2023 | 183 | -346 | -214 | -211 | N/A |
3/31/2023 | 153 | -341 | -204 | -202 | N/A |
12/31/2022 | 133 | -356 | -197 | -194 | N/A |
9/30/2022 | 109 | -274 | -214 | -208 | N/A |
6/30/2022 | 99 | -263 | -210 | -203 | N/A |
3/31/2022 | 90 | -274 | -216 | -208 | N/A |
12/31/2021 | 78 | -281 | -232 | -222 | N/A |
9/30/2021 | 63 | -297 | -247 | -239 | N/A |
6/30/2021 | 47 | -303 | -250 | -242 | N/A |
3/31/2021 | 29 | -292 | -218 | -210 | N/A |
12/31/2020 | 15 | -282 | -183 | -179 | N/A |
9/30/2020 | 4 | -249 | -152 | -150 | N/A |
6/30/2020 | 0 | -209 | -129 | -126 | N/A |
3/31/2020 | 0 | -186 | -141 | -138 | N/A |
12/31/2019 | 0 | -159 | -109 | -106 | N/A |
9/30/2019 | 1 | -155 | -108 | -104 | N/A |
6/30/2019 | 3 | -146 | -103 | -97 | N/A |
3/31/2019 | 4 | -143 | -112 | -105 | N/A |
12/31/2018 | 4 | -143 | -111 | -104 | N/A |
9/30/2018 | 3 | -138 | -107 | -102 | N/A |
6/30/2018 | 1 | -136 | -101 | -98 | N/A |
3/31/2018 | 0 | -128 | -89 | -85 | N/A |
12/31/2017 | 0 | -121 | N/A | -95 | N/A |
9/30/2017 | 0 | -111 | N/A | -80 | N/A |
6/30/2017 | 0 | -99 | N/A | -73 | N/A |
3/31/2017 | 0 | -97 | N/A | -65 | N/A |
12/31/2016 | 0 | -89 | N/A | -60 | N/A |
9/30/2016 | 0 | -85 | N/A | -63 | N/A |
6/30/2016 | 0 | -86 | N/A | -62 | N/A |
3/31/2016 | 0 | -78 | N/A | -58 | N/A |
12/31/2015 | 0 | -73 | N/A | -56 | N/A |
9/30/2015 | 0 | -66 | N/A | -48 | N/A |
6/30/2015 | 0 | -60 | N/A | -47 | N/A |
3/31/2015 | 0 | -57 | N/A | -47 | N/A |
12/31/2014 | 0 | -63 | N/A | -55 | N/A |
9/30/2014 | 1 | -49 | N/A | -60 | N/A |
6/30/2014 | 1 | -48 | N/A | -54 | N/A |
3/31/2014 | 1 | -38 | N/A | -62 | N/A |
12/31/2013 | 1 | 0 | N/A | -48 | N/A |
9/30/2013 | 0 | -10 | N/A | -49 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RVNC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RVNC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RVNC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RVNC's revenue (22.6% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: RVNC's revenue (22.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RVNC is forecast to be unprofitable in 3 years.